This document is a published patent application from the USPTO for a new compound, phthalazine derivatives, intended for use as pyruvate kinase modulators. The application, US20260085061A1, was filed by Sitryx Therapeutics Limited and lists David COUSIN and Oscar BARBA as inventors. The application details a compound of formula (Ia) and related aspects, with CPC classifications including C07D 401/14 and A61K 31/502.

This filing represents a new intellectual property claim and does not impose immediate regulatory obligations on other entities. However, it signals potential future developments in drug discovery and may impact the competitive landscape for companies involved in developing treatments that modulate pyruvate kinase. Compliance officers in the pharmaceutical sector should be aware of this application as it pertains to potential new therapeutic agents.